Brief: I-Mab - I-Mab Regains Global Rights To Lemzoparlimab
22/09/2023 22:46
I-Mab IMAB.O :
* I-MAB - I-MAB REGAINS GLOBAL RIGHTS TO LEMZOPARLIMAB
Source text for Eikon: ID:
Further company coverage: IMAB.O
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview